Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 5
HOS-086159 · Präparat HOS-083284
Microsomal Lomitapide Increased plasma concentrations of lomitapide
triglyceride transfer (see section 4.5).
protein (MTTP)
inhibitor
PDE5 inhibitors Avanafil Increased plasma concentrations of avanafil
(see section 4.4. and 4.5).
Sildenafil Contraindicated when used for the treatment of
pulmonary arterial hypertension (PAH) only.
Increased plasma concentrations of sildenafil.
Thereby, increasing the potential for sildenafil-
associated adverse events (which include
hypotension and syncope). See section 4.4 and
section 4.5 for co-administration of sildenafil in
patients with erectile dysfunction.
Vardenafil Increased plasma concentrations of vardenafil
(see section 4.4. and 4.5).
Sedatives/hypnotics Clorazepate, diazepam, Increased plasma concentrations of clorazepate,
estazolam, flurazepam, diazepam, estazolam, flurazepam, oral
oral midazolam and midazolam and triazolam. Thereby, increasing
triazolam the risk of extreme sedation and respiratory
depression from these agents. (For caution on
parenterally administered midazolam, see
section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lomitapide (HOS-086160) avanafil (HOS-086161) sildenafil (HOS-086162) vardenafil (HOS-086163) clorazepate (HOS-086164) diazepam (HOS-085904) estazolam (HOS-086165) flurazepam (HOS-086166) midazolam (HOS-086167) triazolam (HOS-086168)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 08cb4669d26fd4170f47a5f99fcf18bde7e922c35f378d07e3e1c1cab8b82945 · Zeichen 6375–8447 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 37
HOS-086390 · Präparat HOS-083284
Microsomal Lomitapide Increased plasma concentrations of lomitapide
triglyceride transfer (see section 4.5).
protein (MTTP)
inhibitor
PDE5 inhibitor Avanafil Increased plasma concentrations of avanafil
(see section 4.4. and 4.5).
Sildenafil Contraindicated when used for the treatment of
pulmonary arterial hypertension (PAH) only.
Increased plasma concentrations of sildenafil.
Thereby, increasing the potential for sildenafil-
associated adverse events (which include
hypotension and syncope). See section 4.4 and
section 4.5 for co-administration of sildenafil in
patients with erectile dysfunction.
Vardenafil Increased plasma concentrations of vardenafil
(see section 4.4. and 4.5).
Sedatives/hypnotics Clorazepate, diazepam, Increased plasma concentrations of clorazepate,
estazolam, flurazepam, diazepam, estazolam, flurazepam, oral
oral midazolam and midazolam and triazolam. Thereby, increasing
triazolam the risk of extreme sedation and respiratory
depression from these agents. (For caution on
parenterally administered midazolam, see
section 4.5.).
Ritonavir medicinal product level decreased
Herbal Preparation St. John’s Wort Herbal preparations containing St John’s wort
(Hypericum perforatum) due to the risk of
decreased plasma concentrations and reduced
clinical effects of ritonavir (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): flurazepam (HOS-086166) midazolam (HOS-086167) triazolam (HOS-086168) lomitapide (HOS-086160) avanafil (HOS-086161) sildenafil (HOS-086162) vardenafil (HOS-086163) clorazepate (HOS-086164) diazepam (HOS-085904) estazolam (HOS-086165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 235db82cd2afd722d3066659d7d625c3a96a3162e89ca0b2b4a6f83e7ca9d95d · Zeichen 6173–8675 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 23–24
HOS-116425 · Präparat HOS-094447
23
For the treatment of Not studied. Concomitant use of A safe and effective dose of
pulmonary arterial sildenafil or tadalafil for the treatment of sildenafil for the treatment of
hypertension pulmonary arterial hypertension and pulmonary arterial hypertension
Sildenafil boosted PREZISTA may increase plasma co-administered with boosted
Tadalafil concentrations of sildenafil or tadalafil. PREZISTA has not been
(CYP3A inhibition) established. There is an increased
potential for sildenafil-associated
adverse events (including visual
disturbances, hypotension,
prolonged erection and syncope).
Therefore, co-administration of
boosted PREZISTA and sildenafil
when used for the treatment of
pulmonary arterial hypertension is
contraindicated (see section 4.3).
Co-administration of tadalafil for
the treatment of pulmonary arterial
hypertension with boosted
PREZISTA is not recommended.
PROTON PUMP INHIBITORS
Omeprazole # Boosted PREZISTA can be
darunavir AUC ↔
20 mg once daily #
darunavir Cmin ↔ co-administered with proton pump
#
darunavir Cmax ↔ inhibitors without dose
adjustments.
SEDATIVES/HYPNOTICS
Buspirone Not studied. Sedative/hypnotics are Clinical monitoring is
Clorazepate extensively metabolised by CYP3A. recommended when
Diazepam Co-administration with boosted co-administering boosted
Estazolam PREZISTA may cause a large increase in PREZISTA with these
Flurazepam the concentration of these medicines. sedatives/hypnotics and a lower
Midazolam (parenteral) dose of the sedatives/hypnotics
Zolpidem should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sildenafil (HOS-086162) tadalafil (HOS-086316) omeprazole (HOS-085912) buspirone (HOS-086325) clorazepate (HOS-086164) diazepam (HOS-085904) estazolam (HOS-086165) flurazepam (HOS-086166) midazolam (HOS-086167) zolpidem (HOS-086327)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 9634d5188deeb063704d3dec6fa9fde3f4c10970d03131c50c223d1e001e36d7 · Zeichen 72803–75985 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 65–66
HOS-116532 · Präparat HOS-094447
65
For the treatment of Not studied. Concomitant use of A safe and effective dose of
pulmonary arterial sildenafil or tadalafil for the treatment of sildenafil for the treatment of
hypertension pulmonary arterial hypertension and pulmonary arterial hypertension
Sildenafil darunavir co-administered with low dose co-administered with PREZISTA
Tadalafil ritonavir may increase plasma and low dose ritonavir has not
concentrations of sildenafil or tadalafil. been established. There is an
(CYP3A inhibition) increased potential for
sildenafil-associated adverse
events (including visual
disturbances, hypotension,
prolonged erection and syncope).
Therefore, co-administration of
PREZISTA with low dose
ritonavir and sildenafil when used
for the treatment of pulmonary
arterial hypertension is
contraindicated (see section 4.3).
Co-administration of tadalafil for
the treatment of pulmonary arterial
hypertension with PREZISTA and
low dose ritonavir is not
recommended.
PROTON PUMP INHIBITORS
Omeprazole # PREZISTA co-administered with
darunavir AUC ↔
20 mg once daily #
darunavir Cmin ↔ low dose ritonavir can be
#
darunavir Cmax ↔ co-administered with proton pump
inhibitors without dose
adjustments.
SEDATIVES/HYPNOTICS
Buspirone Not studied. Sedative/hypnotics are Clinical monitoring is
Clorazepate extensively metabolised by CYP3A. recommended when
Diazepam Co-administration with co-administering PREZISTA with
Estazolam PREZISTA/ritonavir may cause a large these sedatives/hypnotics and a
Flurazepam increase in the concentration of these lower dose of the
Midazolam (parenteral) medicines. sedatives/hypnotics should be
Zolpidem considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sildenafil (HOS-086162) tadalafil (HOS-086316) ritonavir (HOS-084521) omeprazole (HOS-085912) buspirone (HOS-086325) clorazepate (HOS-086164) diazepam (HOS-085904) estazolam (HOS-086165) flurazepam (HOS-086166) midazolam (HOS-086167) zolpidem (HOS-086327)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage d55e033062b465321f1e7d6496fca1203bde2ceee842c6b87a58cc57f689d470 · Zeichen 63956–67534 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 21–22
HOS-134522 · Präparat HOS-097580
21
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Geometric mean change Recommendations concerning co-
therapeutic areas (%) administration
For the treatment of Not studied. Concomitant use of A safe and effective dose of
pulmonary arterial sildenafil or tadalafil for the treatment sildenafil for the treatment of
hypertension of pulmonary arterial hypertension and pulmonary arterial hypertension co-
Sildenafil darunavir co-administered with low administered with darunavir and
Tadalafil dose ritonavir may increase plasma low dose ritonavir has not been
concentrations of sildenafil or tadalafil. established. There is an increased
(CYP3A inhibition) potential for sildenafil- associated
adverse events (including visual
disturbances, hypotension,
prolonged erection and syncope).
Therefore, co- administration of
darunavir with low dose ritonavir
and sildenafil when used for the
treatment of pulmonary arterial
hypertension is contraindicated (see
section 4.3). Co-administration of
tadalafil for the treatment of
pulmonary arterial hypertension
with darunavir and low dose
ritonavir is not recommended.
PROTON PUMP INHIBITORS
Omeprazole #
darunavir AUC ↔ Darunavir co-administered with low
20 mg once daily #
darunavir Cmin ↔ dose ritonavir can be co-
#
darunavir Cmax ↔ administered with proton pump
inhibitors without dose adjustments.
SEDATIVES/HYPNOTICS
Buspirone Not studied. Sedative/hypnotics are Clinical monitoring is
Clorazepate extensively metabolised by CYP3A. recommended when co-
Diazepam Co-administration with administering darunavir with these
Estazolam darunavir/ritonavir may cause a large sedatives/hypnotics and a lower
Flurazepam increase in the concentration of these dose of the sedatives/hypnotics
Midazolam medicines. should be considered.
(parenteral)
Zolpidem If parenteral midazolam is co- If parenteral midazolam is co-
administered with darunavir co- administered with darunavir with
administered with low dose ritonavir it low dose ritonavir, it should be
may cause a large increase in the done in an intensive care unit (ICU)
concentration of this benzodiazepine. or similar setting, which ensures
Data from concomitant use of close clinical monitoring and
parenteral midazolam with other appropriate medical management in
protease inhibitors suggest a possible case of respiratory depression
3-4 fold increase in midazolam plasma and/or prolonged sedation. Dose
levels. adjustment for midazolam should be
considered, especially if more than
a single dose of midazolam is
administered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sildenafil (HOS-086162) tadalafil (HOS-086316) ritonavir (HOS-084521) omeprazole (HOS-085912) buspirone (HOS-086325) clorazepate (HOS-086164) diazepam (HOS-085904) estazolam (HOS-086165) flurazepam (HOS-086166) midazolam (HOS-086167) zolpidem (HOS-086327) protease (HOS-085623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 4418dc5e5d870dbdffdec96577360a7846fd09dd38b08120ab6e36d180a150e5 · Zeichen 64193–68705 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 63–64
HOS-134634 · Präparat HOS-097580
63
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Recommendations concerning co-
therapeutic areas Geometric mean change (%) administration
For the treatment of Not studied. Concomitant use of A safe and effective dose of sildenafil
pulmonary arterial sildenafil or tadalafil for the for the treatment of pulmonary
hypertension treatment of pulmonary arterial arterial hypertension co-administered
Sildenafil hypertension and boosted darunavir with boosted darunavir has not been
Tadalafil may increase plasma concentrations established. There is an increased
of sildenafil or tadalafil. potential for sildenafil-associated
(CYP3A inhibition) adverse events (including visual
disturbances, hypotension, prolonged
erection and syncope). Therefore, co-
administration of boosted darunavir
and sildenafil when used for the
treatment of pulmonary arterial
hypertension is contraindicated (see
section 4.3).
Co-administration of tadalafil for the
treatment of pulmonary arterial
hypertension with boosted darunavir
is not recommended.
PROTON PUMP INHIBITORS
Omeprazole #
darunavir AUC ↔ Boosted darunavir can be co-
20 mg once daily #
darunavir Cmin ↔ administered with proton pump
#
darunavir Cmax ↔ inhibitors without dose adjustments.
SEDATIVES/HYPNOTICS
Buspirone Not studied. Sedative/hypnotics are Clinical monitoring is recommended
Clorazepate extensively metabolised by when co-administering boosted
Diazepam CYP3A. Co-administration with darunavir with these
Estazolam boosted darunavir may cause a sedatives/hypnotics and a lower dose
Flurazepam large increase in the concentration of the sedatives/hypnotics should be
Midazolam (parenteral) of these medicines. considered.
Zolpidem
If parenteral midazolam is co- If parenteral midazolam is co-
administered with boosted administered with boosted darunavir,
darunavir it may cause a large it should be done in an intensive care
increase in the concentration of this unit (ICU) or similar setting, which
benzodiazepine. Data from ensures close clinical monitoring and
concomitant use of parenteral appropriate medical management in
midazolam with other protease case of respiratory depression and/or
inhibitors suggest a possible 3-4 prolonged sedation. Dose adjustment
fold increase in midazolam plasma for midazolam should be considered,
levels. especially if more than a single dose
of midazolam is administered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sildenafil (HOS-086162) tadalafil (HOS-086316) omeprazole (HOS-085912) buspirone (HOS-086325) clorazepate (HOS-086164) diazepam (HOS-085904) estazolam (HOS-086165) flurazepam (HOS-086166) midazolam (HOS-086167) zolpidem (HOS-086327) protease (HOS-085623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 6377f4fd304b9d7c6481847fbb0c450071fb1a4848818644923dd1099047eab9 · Zeichen 69529–73658 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.